Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based Vasogen, a biotechnology company, has sold a US patent application and its related foreign counterparts for $400,000.
Subscribe to our email newsletter
This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it relates to its Celacade System.
The company also announced that it continues to advance the process associated with its ongoing strategic review and expects to be in a position to provide a further update to shareholders over the coming weeks. Vasogen added that it has been reviewing various strategic alternatives for the purpose of enhancing shareholder value.